News >

Nilotinib Approved in Europe for Subset of Pediatric CML

Jason M. Broderick @jasoncology
Published: Monday, Nov 20, 2017

Bruno Strigini
Bruno Strigini
The European Commission (EC) has approved nilotinib (Tasigna) for the treatment of pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in the chronic phase (CML-CP), both in the frontline setting and for those with resistance or intolerance to prior therapy including imatinib.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Medical Crossfire®: Personalizing Care for Multiple Myeloma Patients: Current and Future Sequencing StrategiesMay 31, 20191.5
Publication Bottom Border
Border Publication
x